Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company manufacturing and developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New triple therapy takes on pancreatic cancer Results expected Nov 2026 (estimated)
- New antibody drug aims to cut COPD attacks in half Results expected Mar 2027 (estimated)
- New hope for bile duct cancer: experimental drug targets HER2 Results expected May 2027 (estimated)
- New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials Results expected Jun 2027 (estimated)
- New pill TQH3906 tested for tough gut diseases Results expected Jul 2027 (estimated)
-
Experimental diabetes drug AP026 tested in early trial – but study halted
Disease control Stopped earlyThis early-stage trial tested a new drug called AP026, a fusion protein that targets two pathways (GLP-1 and FGF21) to potentially treat type 2 diabetes. The study planned to enroll 74 healthy adults but was terminated early after only 14 participants. The main goal was to check …
Phase 1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental MCL drug trial halted early – what we know
Disease control Stopped earlyThis early-phase trial tested a new drug called TQB3909 in 19 people with mantle cell lymphoma that had returned or stopped responding to treatment. The goal was to find a safe dose and check for side effects. However, the study was terminated early, so we have limited informatio…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental combo targets Hard-to-Treat bone cancer
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—TQB2928 (an antibody that helps the immune system attack cancer cells) and anlotinib (a drug that cuts off tumor blood supply)—in 20 people with advanced osteosarcoma or other solid tumors that had stopped responding to sta…
Phase 1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC